Product Images Citalopram

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Citalopram NDC 50090-5175 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Image - d78873c1 29ce 478b aa3d d1a11a2750ce 01

Image - d78873c1 29ce 478b aa3d d1a11a2750ce 01

image - d78873c1 29ce 478b aa3d d1a11a2750ce 02

image - d78873c1 29ce 478b aa3d d1a11a2750ce 02

This table shows the drug-placebo difference in the number of cases of suicidal behavior per 1000 patients treated, categorized by age range. For patients under 18 years old, there were 14 additional cases of suicidal behavior compared to placebo. For patients over 18 years old, there were decreases in the number of cases compared to placebo, with 564 fewer cases for one drug and 265 fewer cases for another drug.*

image - d78873c1 29ce 478b aa3d d1a11a2750ce 03

image - d78873c1 29ce 478b aa3d d1a11a2750ce 03

This is a table showing the incidence of treatment-emergent adverse events in placebo-controlled clinical trials of Citalopram. The table shows the percentage of patients reporting adverse events in various body systems, such as the autonomic nervous system, central and peripheral nervous system, gastrointestinal system, musculoskeletal system, psychiatric disorders, respiratory system disorders, and urogenital system. The adverse events reported by at least 2% of patients treated with Citalopram are mentioned. The denominator used was for females and males separately in different adverse events.*

image - d78873c1 29ce 478b aa3d d1a11a2750ce 04

image - d78873c1 29ce 478b aa3d d1a11a2750ce 04

This is a table showing the percentage of patients discontinuing the treatment due to adverse events in short-term, placebo-controlled depression trials. The table includes the body system or adverse event and the corresponding percentage for patients taking Citalopram and those on Placebo. The body systems and adverse events listed include General, Gastrointestinal Disorders, Central and Peripheral Nervous System Disorders, and Psychiatric Disorders. There is no non-English character present in the text.*

Label Image - lbl500905175

Label Image - lbl500905175

This is a medication bottle of Citalopram, a drug commonly used to treat depression and anxiety disorders with a strength of 40mg per tablet. The bottle contains 160 tablets and has a label with the name "Stone Rook" on it. The code "Panau:t‘fio 5627-1" represents a unique identifier but its meaning is not clear without further context.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.